10x Genomics navázala spolupráci s Fred Hutchinson Cancer Center s cílem hledat biomarkery rakoviny močového měchýře a detekovat reziduální onemocnění u AML.
Key Takeaways 10x Genomics partners with Fred Hutch to advance biomarker discovery in bladder cancer and AML detection.TXG will use Flex Apex and Xenium to study tumor biology and identify markers linked to treatment response.The collaboration aims to improve AML residual disease detection and expand clinical use of 10x's platforms. 10x Genomics, Inc. (TXG - Free Report) recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia (AML), marking 10x Genomics’ first clinical research initiative extending into hematologic malignancies.
Per management, cancer care has more effective therapies than ever, but there remains a significant need to better identify which treatments will benefit individual patients. 10x Genomics believes single-cell and spatial biology can provide direct insights into the biology that drives treatment response in tumors and blood, supporting the advancement of precision oncology.
TXG Stock Trend Following the NewsFollowing the announcement, TXG stock lost 5.6% at yesterday’s close. Year to date, the stock skyrocketed 366.6%, outperforming the industry’s 15.9% growth and the S&P 500’s 14.5% gain.
The collaboration could strengthen TXG’s long-term growth opportunity by expanding the use of its technology into clinically relevant applications where precise biological information may improve treatment decisions. Successful research outcomes could increase demand for 10x’s platforms among cancer centers and pharmaceutical researchers while creating additional opportunities for biomarker development and clinical testing. The initiative may also help demonstrate the commercial value of TXG’s technology beyond traditional research applications.
TXG currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on the NewsThe bladder cancer project will use TXG’s Flex Apex and Xenium platforms, with plans to incorporate Atera, to examine tumor samples from patients receiving antibody-drug conjugates, immune checkpoint inhibitors and other therapies. Researchers will evaluate drug-target expression and tumor-microenvironment characteristics to identify biological markers associated with treatment response and clinical outcomes.
A second project will investigate whether Flex Apex-based single cell analysis can improve residual disease detection in AML. Current monitoring relies on multiple technologies, creating an opportunity for an integrated approach to identifying residual leukemic cells following treatment.
The collaboration also supports 10x Genomics’ broader efforts to build evidence for clinical applications of its single-cell and spatial technologies. Together with the company’s planned CLIA-certified laboratory, the initiative is expected to contribute to a framework for clinical reporting and help define how cellular and spatial data could support treatment planning in oncology and autoimmune disease.
Industry Prospects Favoring the MarketGoing by the data provided by Grandview Research, the global single-cell analysis market is estimated to reach $6.5 billion in 2026 and is projected to witness a CAGR of 21.7% through 2033.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools, and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News10x Genomics recently announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes. The platform is currently in early access and is expected to launch commercially in early 2027.
10x Genomics recently began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale. Demand for Atera has exceeded the company’s initial 2026 shipment expectations, with booked orders surpassing 40 instruments.
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Torex Gold plánuje letos vrátit akcionářům C$350 milionů a letos očekává asi C$600 milionů volného peněžního toku. Zároveň rozšiřuje Morelos v Mexiku, kde směřuje k produkci téměř 450 000 uncí.
Torex Gold Resources (TSE:TXG) outlined plans to build on production from its Morelos property in Mexico, advance the Los Reyes development project and return capital to shareholders as it seeks to close what it described as a valuation gap.
During a company presentation, Andrew, a Torex speaker, said the company’s strategy rests on “strong execution, visible growth, and disciplined capital allocation.” He said Torex expects to generate about C$600 million in free cash flow this year at current spot prices and plans to use that cash flow for growth investments and shareholder returns.
The company said it expects to return C$350 million to shareholders this year through dividends and share buybacks. The program, initially announced in November and increased in May, includes a dividend yield of about 1%, according to the presentation. Morelos Production and Expansion Plans Torex’s flagship Morelos property in Guerrero State, Mexico, is expected to produce close to 450,000 ounces this year. The company said the asset has a 10-year mine life at an annual production rate of about 450,000 ounces, while providing additional opportunities to extend mine life and increase output.
The company completed construction of the Media Luna underground mine, its second underground operation at Morelos, a year ago. Andrew said Media Luna reached design levels in the first quarter, a year ahead of schedule.
Torex is spending a record C$50 million on drilling this year at Morelos, including work at the ELG and Media Luna underground mines and across the Media Luna cluster. The company recently reported drilling results pointing to a potential mineralized area known as the San Miguel Corridor, extending from Media Luna South to Media Luna East.
Andrew said Torex could increase spending on the corridor next year and drill it from west to east. If drilling progresses as planned, the company could declare an inaugural resource for the area in the first quarter of 2028. He said the corridor’s proximity to Media Luna could allow the company to connect any future resource to existing infrastructure, including the Guajes Tunnel and material-handling systems.
Torex also expects first ore from Media Luna North, which would become its third underground mine at the Morelos property, in December. The company said the new mine would shift Morelos from being mine-constrained to plant-constrained, creating additional options for higher production.
A debottlenecking project could increase processing throughput and production by about 10% with approximately C$10 million of capital investment. Torex said benefits from the debottlenecking work could begin as early as late 2027. A separate plant-expansion study is evaluating an increase in throughput to 14,500 tonnes per day, or about 35% above current throughput. The larger expansion is expected to cost about C$100 million, with a potential decision in the first half of next year. Second-Half Production Expected to Improve Torex produced about 200,000 ounces during the first half of 2026 and expects output to rise significantly during the second half, driven by higher grades, Andrew said. The company’s first-half mine plan included more lower-grade secondary stopes because its paste plant, commissioned after coming online in September of the prior year, limited mining flexibility.
With additional stopes now backfilled, Torex expects to mine higher-grade areas in the second half. Andrew said third-quarter performance was tracking to plan and that the company was comfortable producing around the midpoint of its 2026 guidance.
Los Reyes and Exploration Pipeline Beyond Morelos, Torex is advancing the Los Reyes gold-silver development project in Sinaloa. A preliminary economic assessment issued in July outlined a potential 14-year mine life, with production of 161,000 ounces annually during the first 11 years, estimated all-in sustaining costs of C$1,600 per ounce and C$550 million in capital required to bring the project online.
The company has started a pre-feasibility study that it expects to release in the second half of next year. A feasibility study is planned for 2028, followed by a two-year construction period in 2029 and 2030. Torex said it is targeting production at Los Reyes by 2031.
Torex also has five exploration assets, including Griffin and Medicine Springs in Nevada, and three properties in northern Mexico. The company said it is drilling at four of the five projects this year and will advance them based on results and their ability to compete for capital within its portfolio.
Andrew said Torex is applying for a New York Stock Exchange listing and expects the process to be completed in the coming months. He also said the company has received more permits in Mexico over the past 12 months than in the preceding eight years, describing the permitting environment as improving.
About Torex Gold Resources (TSE:TXG) Torex Gold Resources Inc is a Canadian mining company engaged in the exploration, development, and production of gold, copper, and silver from its flagship Morelos Complex in Guerrero, which is currently Mexico’s largest single gold producer.
10x Genomics spustila první komerční dodávky Atera po mimořádné poptávce. Platforma má posunout prostorovou biologii díky analýze celého transkriptomu s buněčným rozlišením.
Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology.
Introduced in April of this year, Atera brings together whole transcriptome analysis, sub-cellular resolution, single cell sensitivity and unprecedented scale, removing longstanding tradeoffs that have constrained the size, scope and accessibility of spatial studies and expanding the range of biological questions researchers can address. Now, Atera is moving into the hands of researchers around the world, from those scaling existing spatial programs to researchers exploring spatial biology for the first time, across discovery, translational and biopharma research.
Atera's growing reach is matched by the breadth of research now being planned on the platform, spanning biological questions across nearly every major disease area, from oncology and neurodegenerative disease, to autoimmune, inflammatory and cardiometabolic disease and more. Planned applications include foundational cell and tissue atlasing, studies of disease mechanisms and therapeutic response, biomarker research and the generation of large-scale datasets to train AI models of biology.
"We built Atera with the ambition to fundamentally change how researchers measure and understand biology. The remarkable response since launch, and the scale and diversity of the studies now being planned, reinforce our conviction that Atera will do exactly that," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Today is just the beginning. Atera will change how biological research is done, bringing us closer to a future where the complexity of biology is no longer a barrier to understanding disease, developing better treatments and advancing human health."
Demand for Atera has been extraordinary from the start. As previously announced at the company's second-quarter earnings call, booked orders exceeded the 40 instruments that 10x expected to ship in 2026. Since then, momentum has continued to build. Now, as the first instruments begin shipping, that demand is translating into ambitious new research programs designed to take advantage of Atera's combination of breadth, sensitivity and scale.
Discovery Research
The Allen Institute is among the first organizations preparing to put Atera's scale to work. Through early access, researchers used Atera to profile human skin and duodenum tissue, generating whole transcriptome spatial datasets across more than 350,000 cells combined, with high transcript detection and broad transcriptional coverage in both tissues. Now, with three instruments planned to support research across immunology, neuroscience and synthetic biology, the Institute is preparing to take that work even further.
"The Allen Institute is excited to build on our groundbreaking work with Xenium and be among the first to receive Atera. Atera gives our researchers unprecedented power to decode complex tissues and disease states," said Pete Skene, Senior Director, The Allen Institute. "We're thrilled to build on our longstanding partnership with 10x Genomics and unlock a new wave of discoveries."
And the Wellcome Sanger Institute sees Atera opening up new possibilities for research across the institute. "Atera builds on the best features of Xenium in situ technology while advancing capabilities on multiple fronts, pushing the boundaries of scale while providing deeper insights into spatial biology," said Kenny Roberts, PhD, Senior Development Scientist and Technical Spatial Lead at the Wellcome Sanger Institute. "This evolution in spatial capabilities will continue to invigorate not only collaborative global initiatives such as the Human Cell Atlas, but also diverse research projects across our institute and the broader genomics community."
Translational Research
Researchers at the University of Texas MD Anderson Cancer Center are preparing to put Atera to work in translational cancer research.
"Cellular language models are only as powerful as the data they learn from. Atera offers the scale and depth to build high-quality, single-cell spatial maps of patient tissues—capturing not just what cells are doing, but the neighborhoods in which they operate," said Linghua Wang, MD, PhD, Professor of Genomic Medicine and Executive Director & Head, Center for Cellular Language, The University of Texas MD Anderson Cancer Center. "These data can help us move beyond describing how cells respond to therapy toward predicting response and anticipating resistance."
At the Translational Genomics Research Institute (TGen), part of City of Hope, Nicholas Banovich, VP of Scientific Development, and Director of TGen's Center for Spatial Multi Omics (COSMO), and his team are preparing to use Atera across a broad range of translational research applications. "There's been a real gap in the landscape for whole-transcriptome spatial profiling at this combination of sensitivity and throughput. Atera lets us resolve nuanced cell–cell communication and molecular dysregulation enabling novel discovery in large cohorts and providing real opportunities to move this work toward clinical application. We're excited to offer it through COSMO's core services to investigators at TGen, City of Hope, and beyond."
Biopharma
Atera is already gaining significant traction across Biopharma, with nearly all of the world's top 20 R&D-spending biopharma companies either purchasing systems or services through 10x's service lab, Catalyst Research Services. The breadth of this early adoption reflects growing conviction that spatial biology can fundamentally change drug discovery and development.
AI Foundation Models
"Atera is also poised to help advance the vision of virtual biology, where predictive models could allow scientists to ask and answer biological questions digitally at a scale and rate far beyond what is possible today. Realizing that vision will require vast amounts of high-quality biological data. To that end, Biohub plans to use Atera to generate multiomic and morphology data at scale to train AI foundation models that can predict cellular responses to genetic and pharmacologic perturbations," said Andrea Califano, President of Immune Cell Reprogramming at Biohub and Head of Biohub New York.
Xenium to Atera
Atera builds on the strong foundation established by Xenium, giving researchers a path to take successful spatial programs to new levels of scale. The Asia-Pacific Spatial Translational Research Alliance (ASTRA), launched in 2025 by the Garvan Institute of Medical Research and the University of Tokyo to build a pan-cancer spatial atlas, offers an early example. Since then, ASTRA has expanded participation beyond Japan and Australia, and in just one year, reached approximately 50% of its original three-year goal to profile 2,000 tumors. Now, the consortium plans to use Atera to expand the atlas to 5,000 tumors over the next two years. Beyond scale, ASTRA aims to map how cancers evolve against the blueprint of human development, build AI models that predict tumor behavior and discover new therapeutic targets directly from the atlas.
Catalyst Research Services
Atera is gaining traction beyond traditional life sciences research, including at Procter & Gamble (P&G). P&G is enhancing its spatial biology program through 10x's Catalyst Research Services (CRS), specifically to explore how Atera's transformative improvements in spatial biology can propel its skin research forward.
CRS gives researchers more ways to access Atera, and 10x is now preparing to run the first customer samples through the service. In just five months, projects have been booked across more than 100 customers, with a meaningful portion coming from biopharma, highlighting strong early interest in Atera as spatial biology expands into larger-scale translational and drug development research programs.
Roadmap
And what Atera can do today is only the beginning. Atera was designed as a platform that will continue to expand what's possible in spatial biology, with future innovations that will further simplify the experimental workflow, bring together complementary biological information and expand the biological questions researchers can ask. Alongside planned mouse whole transcriptome capabilities, future innovations include:
Slide Prep Automation: A first of its kind capability, future onboard automation of the slide prep workflow will take Atera's easy-to-run workflow even further, automating manual assay steps directly on the instrument. RNA-Protein Multiomics: Future protein capabilities will enable researchers to measure RNA and protein together within the same tissue section, at the same-cell level, combining whole-transcriptome breadth with the functional insight of protein and the flexibility of customizable protein panels. Mutation Detection In Situ: Future, first of its kind, base-by-base sequencing will bring targeted mutation detection directly into the Atera workflow, allowing researchers to read genetic variation alongside gene expression within the same cells and tissue architecture. "The biggest advances in science come when you stop accepting the limitations of what's been possible before and rethink the problem from first principles," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist at 10x Genomics. "That's how we built Atera, and it's how we'll continue to push the platform forward. What we're shipping today is just the foundation. As Atera evolves, it will expand what researchers can do, enabling them to ask increasingly ambitious questions and make discoveries that were previously out of reach."
Additional customer quotes can be found here.
Atera is now shipping to customers worldwide. To learn more about Atera, visit 10xgenomics.com.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended June 30, 2026 and 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
10x Genomics spustila Sentira, cloudovou analytickou platformu pro prostorová biologická data. Díky GPU od NVIDIA zkracuje zpracování z hodin na minuty.
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis. For more than a decade, 10x has pioneered technologies that catalyzed the single cell and spatial biology revolutions, changing how researchers measure and understand biology. Sentira extends that innovation into analysis, giving researchers a faster, easier way to analyze increasingly rich biological data and reach experimental conclusions.
This step beyond data generation comes at an important moment for 10x and spatial biology. With Atera beginning to ship to customers today, spatial whole transcriptome data is becoming faster and easier to generate at scale, enabling increasingly ambitious studies. Yet getting from experiment to biological conclusions has historically required researchers to navigate a fragmented downstream analysis workflow spanning multiple tools, handoffs and areas of expertise. Sentira Spatial aims to change that, creating an integrated experience that brings the journey from spatial sample to insight into one connected ecosystem. By reducing core data processing steps from hours to minutes, researchers can iterate more rapidly, test hypotheses and explore their data in real time, accelerating the path toward actionable biological outcomes.
"Our vision for Sentira is to fundamentally change how researchers turn increasingly complex biological data into experimental conclusions, and Sentira Spatial is just the first step," said Filip Defoort, Senior Vice President, Software at 10x Genomics. "By bringing together our understanding of biology, the technologies that generate the data and the analysis workflows researchers rely on, we can give scientists a faster, more direct path from the questions they ask to the discoveries that follow."
As biological datasets grow in scale and complexity, 10x is collaborating with NVIDIA to make advanced computing capabilities more accessible to researchers. NVIDIA accelerated computing unlocks the spatial workflow, from real-time data processing on the Atera instrument to downstream analysis in Sentira Spatial. With GPU acceleration, Sentira Spatial can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, co-developed by scverse and NVIDIA, which brings GPU acceleration to widely used biological analysis methods. By integrating rapids-singlecell directly into Sentira Spatial, 10x is making GPU-accelerated analysis accessible to more researchers, translating speed into scientific progress without requiring them to build or manage the underlying computing infrastructure themselves.
"Spatial biology is generating datasets of unprecedented scale and complexity, making accelerated computing essential to advancing discovery," said Rory Kelleher, Senior Director of Global Business Development for Life Sciences at NVIDIA. "By combining NVIDIA accelerated computing and rapids-singlecell with 10x Genomics' expertise across spatial data generation and analysis, Sentira can reduce core analysis cycles from hours to minutes—helping researchers iterate faster and focus on uncovering biological insights."
Sentira Spatial is available at no cost through Early Access for researchers using either Xenium or Atera and will continue to expand with new capabilities, including multi-sample analysis to support larger spatial studies. Sentira Spatial is expected to launch commercially in early 2027 as a paid analysis platform, with consumption-based credit pricing and planned enterprise subscription options.
Additional pricing details will be shared at launch.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding our products, services and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended June 30, 2026 and 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Lunit oznámil spolupráci s 10x Genomics, která do výzkumu biomarkerů v onkologii začlení platformu Lunit SCOPE IO pro analýzu H&E snímků a prostorových molekulárních dat.
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery
, /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies.
10x Genomics is a leader in single cell and spatial biology, with its technologies cited in more than 10,000 research publications and enabling discoveries across oncology, immunology, neuroscience and other fields.
The work brings together molecular insights generated using 10x's Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analyzing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to the underlying biology of tumors and identify biomarkers associated with treatment response and resistance.
"10x Genomics has built powerful tools for understanding the molecular organization of tissue," said Brandon Suh, CEO of Lunit. "Lunit SCOPE IO adds the ability to analyze the full H&E landscape at scale. Together, we believe these technologies can help researchers connect deep molecular insight with the tissue patterns that pathologists recognize every day."
"Spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment," said Roman Yelensky, Vice President, Clinical Applications of 10x Genomics. "By combining that molecular depth with Lunit's AI-based analysis of the same H&E images pathologists work with every day, we can give researchers a more complete view of the tumor to accelerate the discovery of biomarkers that could inform treatment strategies and enable potential future diagnostic development."
The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x's broader effort to explore potential future diagnostic applications of spatial technologies in oncology.
Lunit SCOPE IO uses deep learning to analyze whole-slide H&E pathology images and characterize tissue features including tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other features of the tumor microenvironment. Used alongside 10x's spatial technologies, these analyses provide additional tissue context that complements molecular profiling in oncology clinical research.
* Lunit SCOPE IO is for research use only. Not for use in diagnostic procedures.
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Key Takeaways 10x Genomics shares rallied 84.1% in three months as consumables growth and Atera demand strengthened.TXG raised 2026 revenue guidance to $610M-$630M, with 2%-5% growth excluding patent settlements.10x Genomics' instrument revenue fell 47.2%, while its 11.9X forward sales multiple signals a premium. 10x Genomics, Inc. (TXG - Free Report) has surged 84% in the past three months, putting pressure on its fundamentals to keep pace with the stock. Consumables growth, Atera demand and a higher 2026 outlook provide support.
Weak instrument sales, operating losses and an elevated valuation leave less room for disappointment. Comparisons with genomics peers help frame whether TXG can sustain its recent lead.
TXG’s Consumables Momentum Strengthens the Growth CaseConsumables remain the steadier part of TXG’s business. Second-quarter 2026 consumables revenues increased 7% year over year, with Single Cell consumables up 3% as Flex Apex supported double-digit reaction-volume growth.
Spatial consumables rose 16%, primarily driven by Xenium. Recurring usage gives TXG a more durable revenue base than instrument placements, which remain sensitive to funding and capital-spending conditions.
Atera Could Extend TXG’s Spatial Biology OpportunityAtera adds another potential growth leg. Booked orders at the end of the second quarter already greatly exceeded TXG’s roughly 40-unit shipment plan for 2026, indicating strong early demand.
Near-term revenue conversion is constrained by manufacturing capacity, with most 2026 shipments expected in the fourth quarter. Customers are also moderating purchases of existing Spatial instruments before Atera arrives, creating a timing gap between demand and revenues.
How TXG Stacks Up Against ILMN and PACBIllumina, Inc. (ILMN - Free Report) offers a much larger-scale comparison. It reported second-quarter 2026 revenues of $1.16 billion, up 9.5% year over year, with a GAAP operating margin of 21.1%.
Pacific Biosciences of California, Inc. (PACB - Free Report) reported second-quarter revenues of $39.0 million compared with $39.8 million a year earlier, while consumables revenues increased to $20.1 million from $18.9 million. TXG’s recurring consumables growth stands out, but profitability and instrument demand remain key comparison points.
Image Source: Zacks Investment Research
TXG’s Raised Guidance Supports the RallyManagement raised 2026 revenue guidance to $610 million-$630 million from $600 million-$625 million. Excluding nonrecurring patent-settlement revenues in both periods, the updated range represents 2%-5% growth over 2025.
The outlook assumes the academic funding environment remains roughly consistent with recent conditions. The higher guidance therefore does not depend on a funding recovery, though better conditions could improve purchasing activity.
Image Source: Zacks Investment Research
Weak Instruments and Losses Keep Risk ElevatedSecond-quarter instrument revenues declined 47.2% year over year to $7.7 million. Single Cell instrument revenues fell 46.1%, while Spatial instrument revenues dropped 47.8%, reflecting fewer unit sales and the transition ahead of Atera.
TXG also recorded a $19.6 million operating loss despite gross margin reaching 74%. Stronger consumables demand has not yet translated into consistent operating leverage.
TXG’s Valuation Looks Demanding After the RallyTXG trades at 11.9X forward 12-month sales compared with 6.0X for its Zacks sub-industry and a five-year median of 6.3X. The stock therefore carries a sizable premium after its sharp advance.
That valuation raises the execution bar. Continued consumables growth and a smooth Atera ramp may be needed to support the premium as investors weigh TXG against ILMN and PACB.
Style Scores Favor Momentum More Than ValueThe bottom line is that TXG’s operating momentum has improved, but the 84.1% rally already reflects higher expectations. Atera demand and consumables trends provide support, while instrument weakness, losses and valuation limit the margin for error.
TXG currently carries a Zacks Rank #3 (Hold), with a Momentum Score of A, a Growth Score of B, a Value Score of F and a VGM Score of C. The scores favor momentum and growth characteristics more than value, while the Hold rank supports a balanced stance after the recent surge.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways 10x Genomics won over $4.8M after a jury found Parse willfully infringed three licensed patents.The jury upheld all three patents, reinforcing 10x Genomics' single-cell analysis IP portfolio.10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent U.S. injunction. 10x Genomics, Inc. (TXG - Free Report) recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen (QGEN - Free Report) subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.
From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.
Likely Trend of TXG Stock Following the NewsHowever, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.
TXG currently has a market capitalization of $8.02 billion.
Image Source: Zacks Investment Research
Details of the NewsThe U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.
The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.
What's Next for Qiagen's Parse Business?The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.
Industry Prospects Favoring the MarketPer a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
Other NewsRecently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.
Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.
TXG’s Zacks Rank & Key PicksCurrently, TXG has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
10x Genomics (TXG - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +39.13%. A quarter ago, it was expected that this life science technology company would post a loss of $0.29 per share when it actually produced a loss of $0.1, delivering a surprise of +65.52%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $151.04 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.77%. This compares to year-ago revenues of $172.91 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
10x Genomics shares have added about 191% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for 10x Genomics?While 10x Genomics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for 10x Genomics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $147.49 million in revenues for the coming quarter and -$0.78 on $614.51 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, MDxHealth SA (MDXH - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.
This company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
MDxHealth SA's revenues are expected to be $25.8 million, down 3% from the year-ago quarter.
10x Genomics zvýšila celoroční výhled tržeb na 610 až 630 milionů USD z předchozích 600 až 625 milionů USD. Ve 2. čtvrtletí dosáhla tržeb 151,0 milionu USD a čisté ztráty 17,9 milionu USD.
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.
Recent Updates
Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods. Acquired Proteintech Genomics, a division within Proteintech Group, strengthening the company's multiomics strategy by adding advanced protein detection capabilities to its single cell and spatial platforms. Announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance research in diagnostic applications of single cell and spatial technologies for cancer care, furthering the company's diagnostics strategy. "The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead."
Second Quarter 2026 Financial Results
Revenue was $151.0 million for the second quarter of 2026, as compared to $172.9 million for the corresponding period of 2025. Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively, revenue increased 3% over the corresponding period of 2025.
Gross margin was 74% for the second quarter of 2026, as compared to 72% for the corresponding prior year period. The increase in gross margin was primarily due to lower manufacturing costs, which included $2.6 million of tariff refunds, as well as lower inventory write-downs, partially offset by a decrease in non-recurring license and royalty revenue.
Operating expenses were $132.1 million for the second quarter of 2026, a 39% increase from $95.0 million for the corresponding prior year period. The increase was primarily due to a lower gain on settlement of $3.4 million recognized in the second quarter of 2026, as compared to a $40.7 million gain on settlement recognized in the second quarter of 2025. Excluding impacts from settlements, operating expenses were approximately flat year-over-year.
Operating loss was $19.6 million for the second quarter of 2026, as compared to operating income of $30.1 million for the corresponding prior year period.
Net loss was $17.9 million for the second quarter of 2026, as compared to net income of $34.5 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.
2026 Financial Guidance
10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Products and services revenue
$ 149,094
$ 145,157
$ 298,990
$ 282,980
License and royalty revenue
1,942
27,751
2,889
44,811
Revenue (1)
151,036
172,908
301,879
327,791
Cost of products and services revenue (2)
38,539
47,824
83,204
97,262
Gross profit
112,497
125,084
218,675
230,529
Operating expenses:
Research and development (2)
56,791
61,224
113,638
125,469
Selling, general and administrative (2)
78,661
74,434
145,038
164,162
Gain on settlement
(3,400)
(40,700)
(3,400)
(49,900)
Total operating expenses
132,052
94,958
255,276
239,731
Income (loss) from operations
(19,555)
30,126
(36,601)
(9,202)
Other income (expense):
Interest income
4,797
4,271
9,811
7,957
Interest expense
—
(3)
—
(3)
Other income (expense), net
(3,887)
2,603
(4,702)
4,739
Total other income
910
6,871
5,109
12,693
Income (loss) before provision for income taxes
(18,645)
36,997
(31,492)
3,491
Provision for (benefit from) income taxes
(714)
2,459
(91)
3,311
Net income (loss)
$ (17,931)
$ 34,538
$ (31,401)
$ 180
Net income (loss) per share, basic
$ (0.14)
$ 0.28
$ (0.24)
$0.00
Net income (loss) per share, diluted
$ (0.14)
$ 0.28
$ (0.24)
$0.00
Weighted-average shares used to compute net income
(loss) per share, basic
129,984,169
123,755,409
129,050,312
123,183,924
Weighted-average shares used to compute net income
(loss) per share, diluted
129,984,169
124,509,720
129,050,312
124,258,150
(1)
The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Instruments
Single Cell
$ 3,087
$ 5,727
$ 8,310
$ 11,640
Spatial
4,574
8,770
$ 10,613
17,672
Total instruments revenue
7,661
14,497
18,923
29,312
Consumables
Single Cell
88,451
85,788
177,345
169,897
Spatial
42,301
36,397
83,208
67,644
Total consumables revenue
130,752
122,185
260,553
237,541
Services
10,681
8,475
19,514
16,127
Products and services revenue
149,094
145,157
$ 298,990
$ 282,980
License and royalty revenue
1,942
27,751
$ 2,889
$ 44,811
Total revenue
$ 151,036
$ 172,908
$ 301,879
$ 327,791
(1)
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Americas
United States*
$ 82,109
$ 103,491
$ 158,802
$ 190,309
Americas (excluding United States)
2,917
2,667
$ 6,323
6,419
Total Americas
85,026
106,158
165,125
196,728
Europe, Middle East and Africa
39,972
34,734
76,824
66,629
Asia-Pacific
China
14,968
23,170
30,805
40,053
Asia-Pacific (excluding China)
11,070
8,846
29,125
24,381
Total Asia-Pacific
26,038
32,016
59,930
64,434
Total revenue
$ 151,036
$ 172,908
$ 301,879
$ 327,791
* Includes license and royalty revenue.
(2)
Includes stock-based compensation expense as follows:
Wall Street expects a year-over-year decline in earnings on lower revenues when 10x Genomics (TXG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis life science technology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -182.1%.
Revenues are expected to be $146.96 million, down 15% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.73% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for 10x Genomics?For 10x Genomics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +10.93%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that 10x Genomics will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that 10x Genomics would post a loss of$0.29 per share when it actually produced a loss of -$0.10, delivering a surprise of +65.52%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
10x Genomics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerCarlsmed, Inc. (CARL - Free Report) , another stock in the Zacks Medical Info Systems industry, is expected to report loss per share of $0.4 for the quarter ended June 2026. This estimate points to a year-over-year change of +72.8%. Revenues for the quarter are expected to be $18.52 million, up 53.3% from the year-ago quarter.
The consensus EPS estimate for Carlsmed, Inc. has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -18.99%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Carlsmed, Inc. will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
10x Genomics zahájila s CHUV víceletou spolupráci na vývoji biomarkerů, které mají pomoci předpovídat odpověď na léčbu u různých typů rakoviny. Studie bude využívat platformy Flex Apex a Xenium s cílem rozšířit se i na platformu Atera a zahrnout stovky pacientů.
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.
This collaboration builds on 10x's broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies.
Through this multi-year collaboration, the study intends to use 10x's Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumor samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development.
The rapid expansion of targeted therapies, immunotherapies and other emerging treatment modalities is creating new opportunities for treating patients, while also increasing the complexity of treatment decision-making in oncology. As a result, there is a growing need for biomarkers that can help predict which patients are most likely to benefit from specific therapies, supporting more personalized treatment strategies.
"This collaboration brings together complementary expertise in spatial biology, pathology, computational AI and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment," said Raphael Gottardo, Professor and Director of the Biomedical Data Science Center, CHUV. "Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care."
The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.
"The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care."
The collaboration is expected to generate a comprehensive, multimodal resource integrating single cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. It also plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and molecular tumor board decision-making.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
About Lausanne University Hospital (CHUV)
Lausanne University Hospital (CHUV) is one of Switzerland's leading academic medical centers, uniting clinical excellence, biomedical research, and medical education under one roof. Consistently ranked among the world's best hospitals by Newsweek, CHUV also serves as a think tank driving forward research and medicine – bringing together clinicians, pathologists, computational scientists, and translational researchers to accelerate the development of precision medicine. Through multidisciplinary programs spanning cancer research, advanced imaging, digital pathology, artificial intelligence, and spatial biology, CHUV is pioneering next-generation biomarkers and diagnostics – improving patient outcomes and enabling more personalized treatment decisions. To learn more, visit https://www.chuv.ch or connect with us on LinkedIn, Facebook, Instagram, YouTube.
10x Genomics uzavřela víceletou spolupráci s Cleveland Clinic na diagnostice rakoviny močového měchýře. Studie využije platformy Flex Apex a Xenium k hledání biomarkerů, které mohou předpovídat odpověď na léčbu.
Key Takeaways 10x Genomics is collaborating with the Cleveland Clinic on bladder cancer diagnostic applications.The study will use Flex Apex and Xenium to find biomarkers tied to treatment response.The partnership could expand 10x Genomics' role in precision oncology and diagnostics. 10x Genomics (TXG - Free Report) recently entered into a multi-year research collaboration with the Cleveland Clinic to advance novel diagnostic applications for bladder cancer. The study will use the company's Flex Apex and Xenium platforms, with potential expansion to Atera, to identify biomarkers that may predict patient response to antibody-drug conjugates and immunotherapies.
From an investor's perspective, the collaboration marks another step in 10x Genomics' strategy to expand its technologies into clinical and diagnostic applications. The partnership could strengthen the company's position in precision oncology, broaden the use cases for its single-cell and spatial platforms and create long-term growth opportunities in cancer diagnostics.
Likely Trend of TXG Stock Following the NewsShares of TXG have traded flat since the announcement on Wednesday. In the year-to-date period, shares of the company surged 113.1% against the industry’s 20.1% decline. The S&P 500 increased 8.5% in the same time frame.
The collaboration with Cleveland Clinic is likely to strengthen 10x Genomics' long-term growth prospects by generating clinical evidence for the use of its single-cell and spatial technologies in precision oncology. Successful identification of predictive biomarkers could accelerate the adoption of Flex Apex, Xenium and Atera in translational research and future diagnostic applications, expand the company's presence in the high-growth oncology diagnostics market and create new revenue opportunities beyond its core research business.
TXG currently has a market capitalization of $4.08 billion.
Image Source: Zacks Investment Research
More on the NewsUnder the multi-year collaboration, 10x Genomics and the Cleveland Clinic are likely to initially analyze tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens. The study is likely to leverage TXG's Flex Apex and Xenium platforms and could later expand to the recently launched Atera platform. The partners aim to identify clinically relevant biomarkers that may predict patient responses to antibody-drug conjugates and immunotherapies, paving the way for future diagnostic development across multiple tumor types.
The research is likely to integrate single-cell transcriptomic profiling with spatial gene expression and protein measurements to generate a comprehensive view of tumor biology and the tumor microenvironment. Investigators are likely to assess tumor microenvironment composition, immune cell infiltration and the expression of therapeutic targets to better understand mechanisms underlying treatment response and resistance.
The collaboration is expected to generate a rich multimodal dataset linking molecular insights with clinical outcomes, supporting the development of next-generation precision oncology diagnostics and advancing the scientific understanding of bladder cancer.
Favorable Industry Prospect for TXGPer a report by Precedence Research, the global bladder cancer therapeutics diagnostics market size accounted for $5.68 billion in 2025 and is predicted to increase from $6.01 billion in 2026 to approximately $10.04 billion by 2035, expanding at a CAGR of 5.86%.
The bladder cancer diagnostics market is expanding rapidly, driven by the rising prevalence and awareness of the disease, alongside advances in precision medicine, personalized treatment approaches and non-invasive diagnostic technologies.
A Recent Development by TXGRecently, 10x Genomics announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.
Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
